Recently, phase I clinical trials with the STING agonists MIW815 (ADU-S100) and SYNB1891 (an engineered Escherichia coli Nissle strain 1917 expressing STING agonist CDNs under hypoxia) as monotherapy or in combination with immune checkpoint inhibitors (anti-PD1 or anti-PD-L1) have been conducted in patients with solid tumors (including CRC), lymphomas or advanced/metastatic cancers (145–147). Here, STING1 is linked to lymphoma.